COST-EFFECTIVENESS ANALYSIS OF DAPAGLIFLOZIN FOR DIABETIC KIDNEY DISEASE IN MEXICO.
Back
Abstract Number
WCN23-1211
Categories
Chronic Kidney Disease, Hypertension, Diabetes and CVD
Topic - Chronic Kidney Disease, Hypertension, Diabetes and CVD
Diabetic Kidney Disease, Drugs and Treatments
Topic - AKI, Electrolytes, Acid-base Disorders, Tropical Diseases, RPGN and Pregnancy
Topic - Kidney Failure (Former ESKD), incl. Dialysis, Transplantation, Conservative Care
Topic - Special Covid-19
Topic - Education
Abstract Title
COST-EFFECTIVENESS ANALYSIS OF DAPAGLIFLOZIN FOR DIABETIC KIDNEY DISEASE IN MEXICO.
Co-authors
Nava-Vargas, M.G.(1)*;Arellano-Arteaga, K.J.(1);Cortés-Sanabria, L.(2);Andrade-Sierra, J.(3);Márquez-Cabrera, Ó.O.(4);
ie:
Azwin Z.1, Siti Y.1, John D.2
Institution
(1)Nuevo Hospital Civil De Guadalajara Dr. Juan I. Menchaca, Internal Medicine, Guadalajara, Mexico;(2)Centro Médico Nacional De Occidente, Medical Research Unit In Renal Desease, Guadalajara, Mexico;(3)Centro Médico Nacional De Occidente, Medical Research Unit In Renal Desease, Guadalajara, Mexico;(4)Hospital Regional Dr. Valentín Gómez Farías, Nephrology, Zapopan, Mexico;
E-Poster
https://storage.unitedwebnetwork.com/files/1041/d75fd182e3ff9c3eff26696eda1be5af.pdf
Audio File
if any